ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2021

ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases.

Laetitia Pouzol et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.